Technical analysis of Exelixis, Inc. (EXEL): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States.
Price Performance
| 1 month | +13.34% |
| 3 months | +24.83% |
| Year-to-date | +51.04% |
| 1 year | +70.01% |
| 3 years | +221.52% |
| 5 years | +207.76% |
| 10 years | +502.91% |
52-Week Range
| 52-week High | $67.52 |
| 52-week Low | $36.00 |
| Avg Volume (90d) | 2.4M |
Technical Indicators
| SMA 50 | $59.07 |
| SMA 200 | $50.79 |
| Beta | 0.42 |
| 30-day Volatility (annualised) | 20.1% |
| Price vs SMA 50 | +12.1% |
| Price vs SMA 200 | +30.3% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-12 | $43.83 | |
| 2026-01 | $41.36 | -5.6% |
| 2026-02 | $44.06 | +6.5% |
| 2026-03 | $42.89 | -2.7% |
| 2026-04 | $44.46 | +3.7% |
| 2026-05 | $50.48 | +13.5% |
| 2026-06 | $54.41 | +7.8% |
| 2026-07 | $53.03 | -2.5% |
| 2026-08 | $54.64 | +3.0% |
| 2026-08 | $54.64 | +0.0% |
| 2026-09 | $58.41 | +6.9% |
| 2026-10 | $66.20 | +13.3% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-10-29 | $0.89 | $647M |
| 2026-08-05 | $0.85 | $636M |
| 2026-05-05 | $0.77 | $608M |
| 2026-02-10 | $0.77 | $597M |
| 2025-11-04 | $0.69 | $590M |
| 2025-07-28 | $0.65 | $595M |
Price
| Price | $66.20 (closing price, October 29, 2026) |
| Market Cap | $16.6B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 20.75 |
| Price / Book | 9.02 |
| EV / EBITDA | 15.80 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.09 |
| Current Ratio | 3.46 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 12.62 |